Cutaneous T-Cell Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Treatment options commonly used for relapsed/refractory CTCL include:
- Brentuximab vedotin (Adcetris)
- Gemcitabine (Gemzar)
- Mogamulizumab-kpkc (Poteligeo)
- Pralatexate (Folotyn)
- Romidepsin (Istodax)
- Vorinostat (Zolinza)
Learn More
To learn more about CTCL, view the T-Cell Lymphomas Guide. Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].
Additional Resources
To learn more about CTCL, view the T-Cell Lymphomas Guide.
Events
Events
-
-
Understanding and Accessing Chimeric Antigen Receptor (CAR) T-Cell Therapy Webinar
Webinars are hour-long interactive programs discussing the diagnosis and treatment of specific lymphoma subtypes and […]
-
-
Supporting a Loved One with Lymphoma: A Webinar for Care Partners
Program Overview This program is hosted virtually on Zoom and can be accessed online and […]
-
Lymphoma Talk: Houston
The Westin Houston Medical Center/Museum District 1709 Dryden Road, Houston, Texas, United StatesLymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides […]